TX-FLUENCE
2.9.2021 14:02:06 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, and HortiPolaris, a Beijing, China-based greenhouse producing 20 varieties of tomatoes and eight types of lettuce, announced the implementation of Fluence LED lighting solutions into HortiPolaris’s cultivation and research facility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005266/en/
HortiPolaris is a science and technology leader in the region, standing on the cutting edge of farming and education in booming Beijing where the population and demand for fresh, quality produce continues to grow. Its state-of-the-art greenhouse—inspired by the founder’s work in the Netherlands—represents the future of controlled environment agriculture, housing 2,000 square meters of lettuce and 22,850 square meters of tomatoes. HortiPolaris originally equipped its farm with HPS lighting, but found energy costs were too high for a market that valued quality over yield, prompting the company to switch to LED lighting systems that provide crop consistency, energy efficiency and seasonal cultivation flexibility for growers.
“We can use LEDs not only in the winter period, but also in the spring, autumn and even summer to increase yield and stabilize quality,” said Dan Xu, founder and general manager of HortiPolaris. “We are carrying out trials together with Fluence to figure out the best combination of light intensity and light spectrum in order to increase the neutral level to maximize margin and to differentiate ourselves in the market.”
HortiPolaris distributes a variety of popular tomato and lettuce cultivars to local and regional markets and leverages Fluence’s broad-spectrum VYPR LED lighting solutions in its greenhouse and Fluence’s RAZR LED solutions in HortiPolaris’s vertical propagation racks.
“Transitioning from HPS lighting to Fluence LED solutions affords growers a way to improve the quality of their produce such as color and consistency—critical factors shoppers in the growing Beijing region are prioritizing,” said David Cohen, CEO of Fluence. “We are proud to partner with HortiPolaris, an innovator and evolved horticulture leader in the rapidly expanding Chinese market, that recognizes the advantages of LED technology developmentally for crops’ growing cycles and also operationally in facility design.”
Applying Fluence’s LED lighting solutions provides growers better control over plants’ external variables such as temperature and humidity, eliminating once-crucial concerns about overheating as a result of growing under HPS lighting.
“There are several advantages to Fluence lighting solutions,” said Yuchong Chen, technical assistant at HortiPolaris. “Not only can they provide maximum light intensity, but they also allow us to control intensity for different growing stages. Additionally, the uniform light the RAZR fixtures provide is quite important for grafting. That’s why we use Fluence LED lighting solutions in all seasons to increase yield and stabilize the quality of our grow.”
Fluence’s partnership with HortiPolaris bolsters the farm’s ability to harvest quality produce and supply the market year-round. The companies’ ongoing trials to discover optimum lighting strategies for unique cultivation environments are charting the course for the future of innovative food production that will ultimately help the world grow smarter.
To learn more about Fluence, its customers and the company’s ongoing research, visit www.fluence.science/case-studies .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005266/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom